StageZero Life Sciences Ltd (SZLS) - Total Assets

Latest as of September 2024: CA$580.75K CAD ≈ $420.11K USD

Based on the latest financial reports, StageZero Life Sciences Ltd (SZLS) holds total assets worth CA$580.75K CAD (≈ $420.11K USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.

StageZero Life Sciences Ltd - Total Assets Trend (1998–2022)

This chart illustrates how StageZero Life Sciences Ltd's total assets have evolved over time, based on quarterly financial data. Also see SZLS market cap for the company's overall valuation and market capitalisation.

StageZero Life Sciences Ltd - Asset Composition Analysis

Current Asset Composition (December 2022)

StageZero Life Sciences Ltd's total assets of CA$580.75K consist of 38.0% current assets and 62.0% non-current assets. Review SZLS total liabilities to assess the company's total debt and financial obligations.

Asset Category	Amount (CAD)	% of Total Assets
Cash & Equivalents	CA$0.00	2.2%
Accounts Receivable	CA$31.24K	4.5%
Inventory	CA$95.62K	13.7%
Property, Plant & Equipment	CA$434.44K	62.0%
Intangible Assets	CA$0.00	0.0%
Goodwill	CA$0.00	0.0%

Asset Composition Trend (1998–2022)

This chart illustrates how StageZero Life Sciences Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See StageZero Life Sciences Ltd share price for real-time trading data and today's change.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: StageZero Life Sciences Ltd's current assets represent 38.0% of total assets in 2022, a decrease from 60.1% in 1998.
Cash Position: Cash and equivalents constituted 2.2% of total assets in 2022, down from 57.4% in 1998.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1998.
Asset Diversification: The largest asset category is property, plant & equipment at 62.0% of total assets.

StageZero Life Sciences Ltd Competitors by Total Assets

Key competitors of StageZero Life Sciences Ltd based on total assets are shown below.

Company	Country	Total Assets
GeneDx Holdings Corp. NASDAQ:WGS	USA	$481.49 Million
Shanghai Runda Med Tech Co SHG:603108	China	CN¥13.79 Billion
Shanghai Rendu Biotechnology Co. Ltd. A SHG:688193	China	CN¥984.02 Million
DIVA Laboratories Ltd TWO:4153	Taiwan	NT$1.38 Billion
Genoray Co. Ltd KQ:122310	Korea	₩131.23 Billion
RHYTHM Biosciences Ltd AU:RHY	Australia	AU$3.10 Million
Check-Cap Ltd F:7CC	Germany	€7.49 Million
Avricore Health Inc V:AVCR	Canada	CA$584.37K

StageZero Life Sciences Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	0.02	0.04	0.19
Quick Ratio	0.02	0.03	0.14
Cash Ratio	0.00	0.00	0.00
Working Capital	CA$-10.09 Million	CA$-7.98 Million	CA$-3.45 Million

StageZero Life Sciences Ltd - Advanced Valuation Insights

This section examines the relationship between StageZero Life Sciences Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	5.94
Latest Market Cap to Assets Ratio	5.10
Asset Growth Rate (YoY)	-93.4%
Total Assets	CA$700.65K
Market Capitalization	$3.58 Million USD

Valuation Analysis

Premium Asset Valuation: The market values StageZero Life Sciences Ltd's assets at a significant premium (5.10x), suggesting investors see substantial growth potential or unique competitive advantages.

Significant Asset Reduction: StageZero Life Sciences Ltd's assets decreased by 93.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.

Annual Total Assets for StageZero Life Sciences Ltd (1998–2022)

The table below shows the annual total assets of StageZero Life Sciences Ltd from 1998 to 2022.

Year	Total Assets	Change
2022-12-31	CA$700.65K ≈ $506.84K	-93.42%
2021-12-31	CA$10.65 Million ≈ $7.70 Million	+25.13%
2020-12-31	CA$8.51 Million ≈ $6.15 Million	+333.01%
2019-12-31	CA$1.96 Million ≈ $1.42 Million	-20.96%
2018-12-31	CA$2.49 Million ≈ $1.80 Million	-7.71%
2017-12-31	CA$2.69 Million ≈ $1.95 Million	-21.74%
2016-12-31	CA$3.44 Million ≈ $2.49 Million	+501.57%
2015-12-31	CA$572.14K ≈ $413.88K	-80.48%
2014-12-31	CA$2.93 Million ≈ $2.12 Million	-2.09%
2013-12-31	CA$2.99 Million ≈ $2.17 Million	-70.19%
2012-12-31	CA$10.04 Million ≈ $7.26 Million	+146.56%
2011-12-31	CA$4.07 Million ≈ $2.95 Million	-18.49%
2010-12-31	CA$5.00 Million ≈ $3.61 Million	-21.45%
2009-12-31	CA$6.36 Million ≈ $4.60 Million	+6.20%
2008-12-31	CA$5.99 Million ≈ $4.33 Million	-68.54%
2007-12-31	CA$19.03 Million ≈ $13.77 Million	-10.18%
2006-12-31	CA$21.19 Million ≈ $15.33 Million	+141.43%
2005-12-31	CA$8.78 Million ≈ $6.35 Million	-33.24%
2004-12-31	CA$13.15 Million ≈ $9.51 Million	+109.42%
2003-12-31	CA$6.28 Million ≈ $4.54 Million	+204.11%
2002-12-31	CA$2.06 Million ≈ $1.49 Million	-15.76%
2001-12-31	CA$2.45 Million ≈ $1.77 Million	+2.13%
2000-12-31	CA$2.40 Million ≈ $1.74 Million	+6176.70%
1999-12-31	CA$38.23K ≈ $27.65K	-77.27%
1998-12-31	CA$168.21K ≈ $121.68K	--

About StageZero Life Sciences Ltd

TO:SZLS Canada Diagnostics & Research

Market Cap

$3.58 Million

CA$4.94 Million CAD

Market Cap Rank

#29282 Global

#1358 in Canada

Share Price

CA$0.04

Change (1 day)

+0.00%

52-Week Range

CA$0.04 - CA$0.04

All Time High

CA$4.16